PTC Therapeutics Inc. (PTCT)

42.02
0.26 0.61
NASDAQ : Health Technology
Prev Close 42.28
Open 42.40
Day Low/High 41.43 / 42.82
52 Wk Low/High 27.53 / 48.99
Volume 571.63K
Avg Volume 762.70K
Exchange NASDAQ
Shares Outstanding 58.43M
Market Cap 2.55B
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

PTC Therapeutics To Participate At Upcoming Investor Conference

PTC Therapeutics To Participate At Upcoming Investor Conference

SOUTH PLAINFIELD, N.J.

PTC Therapeutics Announces First-Ever Winners Of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders

PTC Therapeutics Announces First-Ever Winners Of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders

- $545,000 awarded to help improve Duchenne muscular dystrophy diagnosis and screening across the globe -

PTC Therapeutics And MRI Interventions Announce Strategic Investment

PTC Therapeutics And MRI Interventions Announce Strategic Investment

- $4 million equity investment to advance delivery device R&D for CNS gene therapy portfolio and other company operations -

PTC Therapeutics To Participate At Upcoming Investor Conferences

PTC Therapeutics To Participate At Upcoming Investor Conferences

SOUTH PLAINFIELD, N.J.

Data From Pivotal FIREFISH And SUNFISH Studies Demonstrate Clinical Benefit Of Risdiplam In Type 1, 2, & 3 Spinal Muscular Atrophy Patients

Data From Pivotal FIREFISH And SUNFISH Studies Demonstrate Clinical Benefit Of Risdiplam In Type 1, 2, & 3 Spinal Muscular Atrophy Patients

Babies with Type 1 SMA from Part 1 of FIREFISH continue to achieve motor milestones including standing

PTC Therapeutics Reports First Quarter 2019 Financial Results And Provides A Corporate Update

PTC Therapeutics Reports First Quarter 2019 Financial Results And Provides A Corporate Update

Translarna™ Approved by Brazilian Health Regulatory Authority (ANVISA)

PTC Therapeutics Breaks Below 200-Day Moving Average - Notable For PTCT

PTC Therapeutics Breaks Below 200-Day Moving Average - Notable For PTCT

In trading on Tuesday, shares of PTC Therapeutics Inc crossed below their 200 day moving average of $37.12, changing hands as low as $37.01 per share. PTC Therapeutics Inc shares are currently trading off about 2.5% on the day.

Translarna™ (ataluren) Is The First Therapy Approved In Brazil For Duchenne Muscular Dystrophy

Translarna™ (ataluren) Is The First Therapy Approved In Brazil For Duchenne Muscular Dystrophy

- Ambulatory Duchenne patients who are 5 years and older with a nonsense mutation can now access a treatment that targets the underlying cause -

PTC Therapeutics To Participate At Upcoming Investor Conferences

PTC Therapeutics To Participate At Upcoming Investor Conferences

SOUTH PLAINFIELD, N.J.

PTC To Expand Product Portfolio In Latin America With WAYLIVRA™

PTC To Expand Product Portfolio In Latin America With WAYLIVRA™

WAYLIVRA, the first and only therapy for the treatment of familial chylomicronemia syndrome (FCS), has received a positive opinion from the CHMP

April 12th Options Now Available For PTC Therapeutics (PTCT)

April 12th Options Now Available For PTC Therapeutics (PTCT)

Investors in PTC Therapeutics Inc saw new options become available today, for the April 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTCT options chain for the new April 12th contracts and identified one put and one call contract of particular interest.

Interesting PTCT Put And Call Options For September 20th

Interesting PTCT Put And Call Options For September 20th

Investors in PTC Therapeutics Inc saw new options begin trading this week, for the September 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 218 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program For Duchenne Muscular Dystrophy

PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program For Duchenne Muscular Dystrophy

- STRIVE Awards have Supported Over 20 Projects in 15 Countries-

Interesting PTCT Put And Call Options For March 22nd

Interesting PTCT Put And Call Options For March 22nd

Investors in PTC Therapeutics Inc saw new options become available today, for the March 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTCT options chain for the new March 22nd contracts and identified one put and one call contract of particular interest.

PTC Therapeutics Launches New Program To Support Research Projects In Rare, Genetic Disorders

PTC Therapeutics Launches New Program To Support Research Projects In Rare, Genetic Disorders

- $500,000 funding to improve Duchenne muscular dystrophy diagnosis and screening in 2019 -

PTC Therapeutics Announces Pricing Of Public Offering Of Common Stock

PTC Therapeutics Announces Pricing Of Public Offering Of Common Stock

SOUTH PLAINFIELD, N.J.

PTC Therapeutics Announces Proposed Public Offering Of Common Stock

PTC Therapeutics Announces Proposed Public Offering Of Common Stock

SOUTH PLAINFIELD, N.J.

PTC Therapeutics Provides Corporate Update And Outlines 5-year Strategic Plan At 2019 J.P. Morgan Healthcare Conference

PTC Therapeutics Provides Corporate Update And Outlines 5-year Strategic Plan At 2019 J.P. Morgan Healthcare Conference

- Multiple products to be launched by 2023 potentially generating ~$1.5 billion revenue annually-

TheStreet Quant Rating: D (Sell)